Therapeutic Area: Other Immune Biology
Real world performance of the CALGB 10403 regimen in young adults in the United States
DaSilva B, et al.
Blood Neoplasia
May 2025
Authors and Affiliates
Brandon DaSilva1,2, Alicia Darwin1, Amy Zhang3, Rutu D. Vyas4, Kathryn Russell5, Jason S.
Gilbert6, Virginia Tan7, Susan Feldt8, Hannah Johnston9, Emily C Liang4,10, Adam S. DuVall9,
Michaela Liedtke11, Wendy Stock9, Ryan D. Cassaday4,5, Marc Schwartz12, Jessica T. Leonard13,
Lori S. Muffly14*, Marlise R. Luskin15
1Department of Medicine, Stanford University School of Medicine, Stanford, CA
2Division of Hematology Oncology, Department of Medicine, Columbia University, New York, NY
3Stanford University School of Medicine, Stanford, CA
4Clinical Research Division Fred Hutchinson Cancer Center, Seattle, WA
5University of Washington School of Medicine, Seattle, WA
6Department of Medicine, University of Colorado School of Medicine, Aurora, CO
7Department of Medicine, Oregon Health & Science University, Portland, OR
8Department of Medicine, University of Chicago, Chicago, IL
9Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL
10Department of Medicine, University of Washington, Seattle, WA
11Stanford Cancer Center, Palo Alto, CA
12Division of Hematology, University of Colorado, Aurora, CO
13Department of Hematology & Medical Oncology, Oregon Health and Science University,
Portland, OR
14Division of Blood and Marrow Transplantation & Cellular Therapy, Stanford University School
of Medicine, Stanford, CA
15Division of Leukemia, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston,
MA
Blood-based Measurable Residual Disease by Clonotypic Mass Spectrometry is Prognostic in Patients with Multiple Myeloma Undergoing Autologous Hematopoietic Cell Transplant
Slade M, et al.
Clin Lymphoma Myeloma Leuk
May 2025
Authors and Affiliates
Michael J. Slade, MD, MSCI1*, Julie Fortier, PhD1, Abir Khaled, PhD2, Mark Fiala, PhD1, Zac McDonald,
PhD2, Mark A. Zaydman, MD, PhD3, Fei Wan, PhD4, Mark A. Schroeder, MD1, Keith Stockerl-Goldstein,
MD1, Liqiang Yang, PhD2, Ravi Vij, MD, MBA1
*Corresponding author
1Division of Oncology, Department of Medicine, Washington University in Saint Louis, St. Louis, MO, USA
2Rapid Novor, Kitchener, Ontario, Canada
3Division of Laboratory and Genomic Medicine, Department of Pathology, Washington University in Saint
Louis, St. Louis, MO, USA
4Division of Public Health Sciences, Washington University in Saint Louis, St. Louis, MO, USA
A phase 2, randomized study of modakafusp alfa as a single agent in patients with relapsed/refractory multiple myeloma
Holstein S, et al.
Blood
April 2025
Authors and Affiliates
Sarah A. Holstein,1 Shebli Atrash,2 Hira Mian,3 Meletios A. Dimopoulos,4
Fredrik Schjesvold,5 Rakesh Popat,6 Nishi Shah,7 Moshe E. Gatt,8 Christian B. Gocke,9
Laurent Frenzel,10 Cyrille Touzeau,11 Meral Beksac,12 Salomon Manier,13 Hila Magen,14
Patrick Travis,15 Omar Nadeem,16 Kaveri Suryanarayan,17 Cheryl Li,17 Shuli Li, 17 Allison
Nelson,17 Dasha Cherepanov,17 Xavier Parot,17 and Dan T. Vogl18
Affiliations:
1. University of Nebraska Medical Center, Omaha, NE, USA
2. Levine Cancer Institute, Charlotte, NC, USA
3. McMaster University, Hamilton, Canada
4. Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian
University of Athens, Athens, Greece; Department of Medicine, Korea University, Seoul,
South Korea
Alexandra Hospital, National and Kapodistrian University of Athens, Athens, Greece
5. Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, Oslo,
Norway
6. University College London Hospital, London, UK
7. Montefiore Medical Center, New York, NY, USA
8. Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem,
Jerusalem, Israel
9. Johns Hopkins University, Baltimore, MD, USA
10. Necker Hospital, Paris, France
11. Centre Hospitalier Universitaire de Nantes, Nantes, France
12. Istinye University Ankara Liv Hospital, Ankara, Turkey
13. Lille University Hospital, Lille, France
14. Department of Hematology Chaim Sheba Medical Center, Ramat-Gan, Faculty of
Medicine, Tel Aviv University, Tel-Aviv, Israel
15. Highlands Oncology Group, Springdale, AR, USA
16. Dana-Farber Cancer Institute, Boston, MA, USA
17. Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA
18. Abramson Cancer Center, Perelman School of Medicine, University of
Pennsylvania, Philadelphia, PA, USA
Establishing measurable residual disease trajectories for patients on treatment for newly diagnosed multiple myeloma as benchmark for deployment of T-cell redirection therapy
Bal S, et al.
Blood Cancer Journal
April 2025
Authors and Affiliates
Susan Bal 1,2,8, Tylan Magnusson1,8, Gayathri Ravi1,2, Smith Giri1,2, Kelly Godby1,2, Binod Dhakal 3, Natalie S. Callander 4,Rebecca W. Silbermann5, Bhagirathbhai Dholaria 6, Vishnu B. Reddy7 and Luciano J. Costa 1,2
1Division of Hematology/Oncology, University of Alabama at Birmingham, Birmingham, AL, USA. 2
O’Neal Comprehensive Cancer Center at University of Alabama at Birmingham,
Birmingham, AL, USA. 3
Division of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA. 4
Division of Hematology, Department of
Medicine, Medical Oncology and Palliative Care, Wisconsin Institutes for Medical Research, Madison, WI, USA. 5
Division of Hematology/Medical Oncology, Knight Cancer Institute,
Oregon Health & Science University, Portland, OR, USA. 6
Department of Medicine, Division of Hematology and Oncology, Vanderbilt University Medical Center, Nashville, TN, USA. 7
Department of Pathology, University of Alabama at Birmingham, Birmingham, AL, USA. 8
These authors contributed equally: Susan Bal, Tylan Magnusson.
Modeling MRD Changes in Myeloma to Understand Treatment Effects, Predict Outcomes, and Investigate Curative Potential
Gregory W, et al.
Clinical Cancer Research
April 2025
Authors and Affiliates
Walter M. Gregory1, Thomas J. Prior2, J. Blake Bartlett3, Pieter Sonneveld4, Meletios A. Dimopoulos5,
Philippe Moreau6, Saad Usmani7, and Thierry Facon8
1Division of Clinical Medicine, University of Sheffield, Sheffield, United Kingdom.
2Janssen Research & Development, Spring House, Pennsylvania. 3Janssen Research
& Development, LLC, Raritan, New Jersey. 4Erasmus MC Cancer Institute,
Rotterdam, the Netherlands. 5Department of Clinical Therapeutics, School of
Medicine, National and Kapodistrian University of Athens, Alexandra General
Hospital, Athens, Greece. 6Hematology Department, University Hospital Hˆotel-
Dieu, Nantes, France. 7Memorial Sloan Kettering Cancer Center, New York, New
York. 8University of Lille, CHU Lille, Lille, France.
Daratumumab for newly diagnosed multiple myeloma: pooled analysis of patients aged >/65 years from GRIFFIN and PERSEUS
Rodriguez-Otero P, et al.
Clinical Lymphoma Myeloma & Leukemia
April 2025
Authors and Affiliates
Paula Rodriguez-Otero,a Peter M. Voorhees,b Mario Boccadoro,c Jacob Laubach,d Hermann
Einsele,e Douglas W. Sborov,f Meletios A. Dimopoulos,g Annemiek Broijl,h Roberto Mina,i
Andrew Spencer,j Fredrik Schjesvold,k Rebecca Silbermann,l Francesca Gay,i Luciano J. Costa,m
Aurore Perrot,n Yanfang Liu,o Jianping Wang,p Anna Sitthi-Amorn,p Robin Carson,p Annelore
Cortoos,q Saad Z. Usmani,r Paul G. Richardson,d Philippe Moreau,s Pieter Sonneveld,h and
Jonathan L. Kaufmant
aDepartment of Hematology, Cancer Center Clínica Universidad de Navarra, Pamplona, Navarra,
Spain; bLevine Cancer Institute, Atrium Health Wake Forest University School of Medicine,
Charlotte, NC, United States; cMyeloma Unit, Division of Hematology, University of Torino,
Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Italy;
dDana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States; eUniversity
Hospital Würzburg, Department of Internal Medicine II, Würzburg, Germany; fHuntsman
Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT, United States;
gNational and Kapodistrian University of Athens, Athens, Greece; hDepartment of Hematology,
EMN/Erasmus MC Cancer Institute, Rotterdam, The Netherlands; iDivision of Hematology 1,
Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, and Department
3
of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy; jMalignant
Haematology and Stem Cell Transplantation Service, Alfred Health-Monash University,
Melbourne, Australia; kOslo Myeloma Center, Department of Hematology, Oslo University
Hospital, Oslo, Norway, and KG Jebsen Center for B-cell Malignancies, University of Oslo,
Oslo, Norway; lKnight Cancer Institute, Oregon Health & Science University, Portland, OR,
United States; mUniversity of Alabama at Birmingham, Birmingham, AL, United States; nCHU
de Toulouse, IUCT-O, Université de Toulouse, UPS, Service d’Hématologie, Toulouse, France;
oJohnson & Johnson, Beijing, China; pJohnson & Johnson, Spring House, PA, United States;
qJohnson & Johnson, Horsham, PA, United States; rMemorial Sloan Kettering Cancer Center,
New York, NY, United States; sHematology Department, University Hospital Hôtel-Dieu,
Nantes, France; tWinship Cancer Institute, Emory University, Atlanta, GA, United States.
Bortezomib, melphalan, and prednisone with or without daratumumab in transplant-ineligible patients with newly diagnosed multiple myeloma (ALCYONE): final analysis of an open-label, randomised, multicentre, phase 3 trial
Mateos M, et al.
Lancet Oncology
April 2025
Authors and Affiliates
Maria-Victoria Mateos, Jesus San-Miguel, Michele Cavo, Kenshi Suzuki, Andrzej Jakubowiak, Stefan Knop, Chantal Doyen, Paulo Lucio,
Zsolt Nagy, Ludek Pour, Sebastian Grosicki, Andre Crepaldi, Anna Marina Liberati, Philip Campbell, Sung-Soo Yoon, Genadi Iosava,
Tomoaki Fujisaki, Mamta Garg, Mai Ngo, Eva G Katz, Maria Krevvata, Kasey Bolyard, Robin Carson, Fredrik Borgsten, Meletios A Dimopoulos
University Hospital of
Salamanca/IBSAL/Cancer
Research Center–IBMCC
(USAL-CSIC), Salamanca, Spain
(M-V Mateos PhD); Cancer
Center Clínica Universidad de
Navarra, CCUN, Centro de
Investigación Médica Aplicada
(CIMA), Instituto de
Investigación Sanitaria de
Navarra (IDISNA), CIBER-ONC,
Pamplona, Spain
(Prof J San-Miguel MD); IRCCS
Azienda Ospedaliero–
Universitaria di Bologna,
Istituto di Ematologia
“Seràgnoli”, Dipartimento di
Scienze Mediche e Chirurgiche,
Università di Bologna,
Bologna, Italy
(Prof M Cavo MD); Department
of Hematology, Japanese Red
Cross Medical Center, Tokyo,
Japan (K Suzuki MD); University
of Chicago Medical Center,
Chicago, IL, USA
(Prof A Jakubowiak MD);
Department of Hematology,
Oncology and Stem Cell
Transplantation, Nuremberg
General Hospital, Paracelsus
Medical School, Nuremberg,
Germany (Prof S Knop MD);
Université Catholique de
Louvain, CHU UCL Namur,
Yvoir, Belgium
(Prof C Doyen MD);
Champalimaud Centre for the
Unknown, Lisbon, Portugal
(P Lucio MD); Department of
Internal Medicine and
Hematology, Semmelweis
University, Budapest, Hungary
(Z Nagy MD); University
Hospital and Masaryk
University Brno, Brno, Czech
Republic (L Pour MD);
Department of Hematology
and Cancer Prevention in
Chorzów, Faculty of Health
Sciences in Bytom, Medical
University of Silesia in
Katowice, Katowice, Poland
(S Grosicki MD); Clinica de
Tratamento E, Cuiaba, Brazil
(A Crepaldi MD); Università
degli Studi di Perugia, Azienda
Ospedaliera Santa Maria, Terni,
Italy (Prof A M Liberati MD);
Andrew Love Cancer Centre,
University Hospital Geelong,
Geelong, VIC, Australia
(P Campbell MD); Department
of Internal Medicine, Seoul
National University College of
Medicine, Seoul, South Korea
(Prof S-S Yoon MD); Medinvest-
Institute of Hematology,
Tbilisi, Georgia (G Iosava MD);
Matsuyama Red Cross Hospital,
Matsuyama, Japan
(T Fujisaki MD); Leicester Royal
Infirmary – Haematology,
Leicester, UK (M Garg MD);
Janssen Research &
Development, LLC, Titusville,
NJ, USA (M Ngo PhD); Janssen
Research & Development, LLC,
Raritan, NJ, USA
(E G Katz PhD; K Bolyard MS,
F Borgsten MD); Janssen
Research & Development, LLC,
Spring House, PA, USA
(M Krevvata PhD, R Carson MD);
Department of Clinical
Therapeutics, School of
Medicine, National and
Kapodistrian University of
Athens, Alexandra General
Hospital, Athens, Greece
(Prof M A Dimopoulos MD)
Optimal MRD-based endpoint to support response-adapted treatment cessation in newly diagnosed multiple myeloma
Giri S, et al.
Blood
April 2025
Authors and Affiliates
Smith Giri MD, MS1, Binod Dhakal MD2, Natalie S Callander MD3, Eva Medvedova MD4, Kelly Godby
MD1, Bhagirathbhai R. Dholaria MD5, Susan Bal MD1, Gayathri Ravi MD1, Saurabh Chhabra MD MS1,
Rebecca W Silbermann MD2, Luciano Costa MD PhD1.
1Division of Hematology and Oncology, Department of Medicine, University of Alabama at Birmingham
School of Medicine, Birmingham, AL
2 Division of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin,
Milwaukee, WI
3Division of Hematology, Medical Oncology and Palliative Care, Department of Medicine, University of
Wisconsin, Madison, WI
4Division of Hematology/Medical Oncology, Knight Cancer Institute, Oregon Health & Science
University, Portland, OR
5Division of Hematology Oncology, Department of Medicine, Vanderbilt University Medical Center,
Nashville, TN
Clinical use of measurable residual disease in adult ALL: recommendations from a panel of US experts
Short N, et al.
March 2025
Authors and Affiliates
Nicholas J. Short,1 Ibrahim Aldoss,2 Daniel J. DeAngelo,3 Marina Konopleva,4 Jessica Leonard,5 Aaron C. Logan,6 Jae Park,7 Bijal Shah,8
Wendy Stock,9 and Elias Jabbour1
1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX; 2Department of Hematology and Hematopoietic Cell Transplantation, City of
Hope, Duarte, CA; 3Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; 4Department of Oncology, Montefiore Medical Center, Albert Einstein
College of Medicine, Bronx, NY; 5Division of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR; 6Division of
Hematology, Blood and Marrow Transplantation, and Cellular Therapy, Department of Medicine, University of California San Francisco, San Francisco, CA; 7Memorial Sloan
Kettering Cancer Center, New York, NY; 8Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL; and 9Department of Medicine Section of Hematology-
Oncology, University of Chicago, Chicago, IL